Bruker Acquires DISQVER® Platform to Boost Infection Detection Capabilities
Event summary
- Bruker Corporation acquired the DISQVER® clinical metagenomics platform from Noscendo GmbH on July 15, 2026.
- DISQVER® enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples.
- The platform can analyze over 11,000 different microbes and parasites in less than 24 hours after sample receipt.
- Financial details of the transaction were not disclosed, and DISQVER® is not expected to be material to Bruker’s FY26 financial results.
The big picture
Bruker’s acquisition of DISQVER® aligns with its strategy to expand into rapid antimicrobial susceptibility testing and molecular diagnostics. This move positions Bruker to better support earlier decision-making in severe infectious diseases, addressing a critical need in the healthcare sector. The deal underscores the growing importance of metagenomic next-generation sequencing in infection detection.
What we're watching
- Regulatory Approval
- Whether Bruker can successfully progress the registration of DISQVER® for diagnostic purposes.
- Market Integration
- The pace at which Bruker integrates DISQVER® into its existing infection detection portfolio.
- Competitive Positioning
- How this acquisition affects Bruker's competitive standing in the clinical metagenomics market.
Related topics